Related Experiment Video
Updated: Jan 22, 2026

Genome Engineering of Primary Human B Cells Using CRISPR/Cas9
Published on: November 3, 2020
Activation of Necroptosis by Engineered Self Tumor-Derived Exosomes Loaded with CRISPR/Cas9
Diana Gulei1, Ioana Berindan-Neagoe2
1MEDFUTURE - Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Marinescu 23 Street, 400337 Cluj-Napoca, Romania.
Abstract:
CRISPR/Cas9 has proved its efficiency in vitro, where we now know that this tool can efficiently target specific parts of the genome. These modifications can be used to generate advanced models of human diseases, address specific functions of genes, and develop new therapeutic strategies. Even if these advancements are promising, there are still two great issues associated with CRISPR/Cas9: how we can specifically and safely deliver the editing tool in vivo and how we can address the impossibility of CRISPR/Cas9 to attack all the cells within the targeted pool? This work presents an alternative method for engagement of cell death in cancer cells with immediate application in the preclinical sector and significant translational relevance toward clinics.
More Related Videos
Related Concept Videos
CRISPR
What is Genetic Engineering?
CRISPR/Cas9 Genome Editing
CRISPR and crRNAs
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
Overview of Exosomes
Stahl et al. discovered exosomes in 1983, but the exosomes were initially considered waste products released from the...
Impact Loading
In cases of elastic deformation,...

